Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nanoliposomal irinotecan + cadonilimab
- Development stage
- Unknown
- Lead developer
- Akeso
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
This combination therapy pairs nanoliposomal irinotecan, a cytotoxic topoisomerase I inhibitor, with cadonilimab (AK104), a first-in-class PD-1/CTLA-4 bispecific antibody. Nanoliposomal irinotecan utilizes a liposomal delivery system to improve the pharmacokinetics and tumor accumulation of irinotecan's active metabolite, SN-38, thereby reducing systemic toxicity compared to conventional irinotecan. Cadonilimab simultaneously blocks the Programmed Cell Death Protein 1 (PD-1) and Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) immune checkpoints, enhancing T-cell activation and anti-tumor immunity. The combination is primarily being evaluated for the treatment of small cell lung cancer (SCLC), particularly in patients who have progressed on prior platinum-based therapies, aiming to leverage the synergistic effects of chemotherapy-induced immunogenic cell death and dual checkpoint inhibition.
- Brand names
- Kaitani
- Other names
- irinotecan liposome + cadonilimabnal-IRI + cadonilimab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on nanoliposomal irinotecan + cadonilimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nanoliposomal irinotecan + cadonilimab.